UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036254
Receipt number R000041239
Scientific Title Safety of Consecutive Intake of a Test Food.
Date of disclosure of the study information 2019/03/19
Last modified on 2019/09/17 10:37:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety of Consecutive Intake of a Test Food.

Acronym

Safety of Consecutive Intake of a Test Food.

Scientific Title

Safety of Consecutive Intake of a Test Food.

Scientific Title:Acronym

Safety of Consecutive Intake of a Test Food.

Region

Japan


Condition

Condition

N/A(healthy adults)

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study examines safety of consecutive intake (4 weeks) of a test food.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

[1]Existence and its contents of side effects: expression number and expression rate of side effects (expression rate: number of cases/number of cases analyzed) (during analyzing test results).

Key secondary outcomes

*Secondary outcomes
[1]Adverse events: number of cases and expression rate of adverse events (expression rate: number of cases/number of cases analyzed) (Week 0, Week 4).
[2]Blood pressure, pulsation (Week 0, Week 4).
[3]Weight, body fat percentage, BMI (Week 0, Week 4).
[4]Hematologic test (Week 0, Week 4).
[5]Blood biochemical test (Week 0, Week 4).
[6]Urine analysis (Week 0, Week 4).
[7]Doctor's questions (Week 0, Week 4).

*Other index
[1]Subject's diary (each day during the test period).


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Oral intake of the test product (one pack in a day for 4 weeks).

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Male

Key inclusion criteria

[1]Males and females aged 20-65 years.
[2]Individuals who are healthy and have no chronic physical disease including skin disorders.
[3]Individuals whose written informed consent has been obtained.
[4]Individuals who can come to the designated venue for this study and be inspected.
[5]Individuals judged appropriate for the study by the principal.

Key exclusion criteria

[1]Individuals using medical products.
[2]Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia.
[3]Individuals who used a drug to treat a disease in the past 1 month (except temporal usage for pollenosis).
[4]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease.
[5]Individuals who are a patient or have a history of or endocrine disease.
[6]Individuals whose BMI is less than 18.5kg/m2 or over 30.0kg/m2.
[7]Individuals whose systolic and diastolic blood pressures are over 140mmHg and 90mmHg, respectively.
[8]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months.
[9]Individuals who experienced unpleasant feeling during blood drawing.
[10]Individuals who are sensitive to a test product or other foods, and medical products.
[11]Individuals who habitually take the foods for specified health uses (FOSHU) or functional food (except for subjects who can stop consume them after informed consent).
[12]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60mg/day).
[13]Individuals with possible changes of life style, such as conducting a long-term travel, during the test period.
[14]Individuals who are or are possibly, or are lactating.
[15]Individuals who participated in other clinical studies in the past 3 months.
[16]Individuals who are or whose family is engaged in functional foods or cosmetics.
[17]Individuals judged inappropriate for the study by the principal.

Target sample size

12


Research contact person

Name of lead principal investigator

1st name Takahiro
Middle name
Last name Ono

Organization

Ueno-Asagao Clinic

Division name

Head

Zip code

110-0015

Address

Kairaku Building 6F, 2-7-5, Higashiueno, Taito-ku, Tokyo, JAPAN

TEL

+81-3-6240-1162

Email

t.ono@ueno-asagao.clinic


Public contact

Name of contact person

1st name Ryoma
Middle name
Last name Shimizu

Organization

TES Holdings Co., Ltd.

Division name

Administrative Department of Clinical Trials

Zip code

110-0015

Address

Kairaku Building 6F, 2-7-5, Higashiueno, Taito-ku, Tokyo, JAPAN

TEL

+81-3-6801-8480

Homepage URL


Email

r.shimizu@tes-h.co.jp


Sponsor or person

Institute

TES Holdings Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Kracie Foods, Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ueno-Asagao Clinic Ethical Review Committee

Address

Kairaku Building 6F, 2-7-5, Higashiueno, Taito-ku, Tokyo, 110-0015 JAPAN

Tel

+81-3-6240-1162

Email

i.takahashi@tes-h.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 03 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

12

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 02 Month 16 Day

Date of IRB

2019 Year 02 Month 18 Day

Anticipated trial start date

2019 Year 03 Month 15 Day

Last follow-up date

2019 Year 04 Month 17 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 03 Month 19 Day

Last modified on

2019 Year 09 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041239


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name